Lower PSA linked to greater survival with sipuleucel-T in prostate cancer

Sipuleucel-T treatment may be of the most benefit to patients with metastatic castration-resistant prostate cancer who have low prostate specific antigen levels, say US researchers.
Source: MedWire News - Urology - Category: Urology & Nephrology Source Type: news